THE 630
Alternative Names: THE-630Latest Information Update: 08 May 2024
At a glance
- Originator ARIAD Pharmaceuticals
- Developer Concentra Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal stromal tumours
Most Recent Events
- 13 Jul 2023 Discontinued - Phase-I/II for Gastrointestinal stromal tumours (In the elderly, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, In adults) in USA (PO) due to dose-limiting toxicities related to hand-foot skin reaction in Cohort 7 (27 mg) (NCT05160168)
- 02 Jun 2023 Efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Gastrointestinal stromal tumours presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 25 May 2023 Efficacy and adverse events data from a phase I/II trial in Gastrointestinal stromal tumours released by Theseus Pharmaceuticals